Clinical trials: Length of Stay
Hypothermia
Study to Determine the Effects of Pre-warming on OR Patient Temperatures and Surgical Outcomes
The application of active warming to patients whether awake or under general anesthesia has been proven safe in numerous studies and it is common practice to use warmers.
- Trial name
- NCT02177903
- Testing
- Bair Paws Patient Adjustable Warming System
- Where
- Canada
- Volunteers
- 220 people
- Sponsor
- Solventum US LLC
Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the…
- Trial name
- EasyBoost (NCT07357675)
- Testing
- EA-230 90mg/kg/hour
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 300 people
- Sponsor
- EBI Anti Sepsis BV
Ileus
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis.
- Trial name
- NCT01150760
- Testing
- Alvimopan
- Where
- United States
- Volunteers
- 7,050 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
SARS-CoV-2 Infection
Burn Injuries During COVID-19 Pandemic and Its Influence on Length of Stay
Burn injuries were thought to be difficult to treat during the new corona virus epidemic. Our goal is to determine the risk factors that influence length of hospital stay (LOS) of burn injured patients during COVID -19 pandemic.
- Trial name
- NCT06330389
- Testing
- Burn Injuries Graft Surgery
- Where
- Qatar
- Volunteers
- 70 people
- Sponsor
- Hamad Medical Corporation
Pulmonary Embolism (PE), Pulmonary Thromboembolism
The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
A study based on a chart review of participants that presented with a sudden blood clot in the lung
- Trial name
- NCT03595891
- Testing
- Non-Interventional
- Where
- United Kingdom
- Volunteers
- 660 people
- Sponsor
- Bristol-Myers Squibb
Reduction in the Initial Length of Stay
An Evaluation of Multisense® to Ensure a Safe Return Home Following High-risk Gastrointestinal Surgery, Compared With Standard Care.
The SENSE-ECO study is a prospective, randomized trial of 490 high-risk patients designed to show that the MultiSense® remote monitoring patch safely reduces hospital stays following major digestive surgery.
- Trial name
- SENSE-ECO (NCT07552805)
- Testing
- Monitoring by MultiSense®
- Where
- 9 sites in France
- Volunteers
- 490 people
- Sponsor
- Rhythm Diagnostic Systems
Infant, Extremely Premature, Length of Stay
Trial of Patterned Oral Somatosensory Entrainment for Shortening Time to Oral Feeding
The primary hypothesis is that the preterm infants (26 0/7 to 30 6/7 weeks gestational age) who undergo the NTrainer System® training will transition to full oral feeds faster than the control group (i.e.
- Conditions
- Infant, Extremely Premature, Length of Stay, Feeding
- Trial name
- NCT01158391
- Testing
- NTrainer® Intervention, Control Intervention
- Where
- 5 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- KC BioMediX, Inc
Ischemic Stroke
Study of the Guardian System on Motor Recovery and Impact on Length of Stay in Ischemic Stroke Patients
This is a non-blinded randomized study that will investigate whether the use of a novel, non-invasive perfusion enhancement system (The Guardian System) impacts motor recovery and hospital length of stay in acute ischemic stroke…
- Trial name
- NCT03673241
- Testing
- Guardian System
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- TurnCare Inc.
Severe Sepsis
Effect of a Sepsis Prediction Algorithm on Clinical Outcomes
In this clinical outcomes analysis, the effect of a machine learning algorithm for severe sepsis prediction on in-hospital mortality, hospital length of stay, and 30-day readmission was evaluated.
- Trial name
- NCT03960203
- Testing
- InSight
- Volunteers
- 75,147 people, healthy volunteers welcome
- Sponsor
- Dascena
Acute Respiratory Distress Syndrome
Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis
This study was conducted to determine the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Secretome in severe ARDS patients.
- Trial name
- NCT07439848
- Testing
- Control (NaCl 0.9%), UC-MSC, UC-MSC and Secretome
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Hyponatremia, Dilutional Hyponatremia
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction.
- Conditions
- Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome
- Trial name
- SALACIA (NCT01227512)
- Testing
- tolvaptan, Fluid Restriction
- Where
- 56 sites in United States
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Atrial Fibrillation
Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
The primary objective of this study is to compare the Length of Stay from treatment of oral anticoagulant initiation to hospital discharge of patients hospitalized and subsequently treated with dabigatran or warfarin for…
- Trial name
- NCT02631057
- Testing
- Dabigatran, Warfarin
- Where
- 2 sites in Japan
- Volunteers
- 4,313 people
- Sponsor
- Boehringer Ingelheim
Average Length of Stay, Surgery
Assessment of the Feasibility and Organisational Impact of a Care Pathway Incorporating the MultiSense® Medical Device for Post-operative Home Monitoring of Elderly Patients.
Assessing the clinical and organisational impact of a home-based post-operative monitoring strategy incorporating the MultiSense® device involving 80 patients aged 65 years and over who have undergone major surgery.
- Trial name
- IMPACT - MS (NCT07514286)
- Testing
- Monitoring by MultiSense
- Where
- 4 sites in France
- Volunteers
- 80 people
- Sponsor
- Rhythm Diagnostic Systems